These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22878095)

  • 41. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection.
    Zhao X; Tang ZY; Klumpp B; Wolff-Vorbeck G; Barth H; Levy S; von Weizsäcker F; Blum HE; Baumert TF
    J Clin Invest; 2002 Jan; 109(2):221-32. PubMed ID: 11805134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
    Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J
    J Virol; 2018 May; 92(10):. PubMed ID: 29491159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.
    Douam F; Bobay LM; Maurin G; Fresquet J; Calland N; Maisse C; Durand T; Cosset FL; Féray C; Lavillette D
    J Virol; 2016 Jan; 90(2):992-1008. PubMed ID: 26537674
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
    Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
    Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism of cell infection with hepatitis C virus (HCV)--a new paradigm in virus-cell interaction.
    Budkowska A
    Pol J Microbiol; 2009; 58(2):93-8. PubMed ID: 19824391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process.
    Baktash Y; Madhav A; Coller KE; Randall G
    Cell Host Microbe; 2018 Mar; 23(3):382-394.e5. PubMed ID: 29544098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis C virus utilizes VLDLR as a novel entry pathway.
    Ujino S; Nishitsuji H; Hishiki T; Sugiyama K; Takaku H; Shimotohno K
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):188-93. PubMed ID: 26699506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism.
    Douam F; Fusil F; Enguehard M; Dib L; Nadalin F; Schwaller L; Hrebikova G; Mancip J; Mailly L; Montserret R; Ding Q; Maisse C; Carlot E; Xu K; Verhoeyen E; Baumert TF; Ploss A; Carbone A; Cosset FL; Lavillette D
    PLoS Pathog; 2018 Mar; 14(3):e1006908. PubMed ID: 29505618
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis C virus infection and tight junction proteins: The ties that bind.
    Mailly L; Baumert TF
    Biochim Biophys Acta Biomembr; 2020 Jul; 1862(7):183296. PubMed ID: 32268133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis C virus entry: potential receptors and their biological functions.
    Cocquerel L; Voisset C; Dubuisson J
    J Gen Virol; 2006 May; 87(Pt 5):1075-1084. PubMed ID: 16603507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Steps and Routes of HCV Infection: The Great Promise of New Anti-Viral Targets.
    Crema A; Ponzetto A; Clementi M; Carloni G
    Curr Drug Targets; 2015; 16(7):757-70. PubMed ID: 25694122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Entry and replication of recombinant hepatitis C viruses in cell culture.
    Vieyres G; Pietschmann T
    Methods; 2013 Feb; 59(2):233-48. PubMed ID: 23009812
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A human claudin-1-derived peptide inhibits hepatitis C virus entry.
    Si Y; Liu S; Liu X; Jacobs JL; Cheng M; Niu Y; Jin Q; Wang T; Yang W
    Hepatology; 2012 Aug; 56(2):507-15. PubMed ID: 22378192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins.
    Hopcraft SE; Evans MJ
    Hepatology; 2015 Oct; 62(4):1059-69. PubMed ID: 25820616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans.
    Xu Y; Martinez P; Séron K; Luo G; Allain F; Dubuisson J; Belouzard S
    J Virol; 2015 Apr; 89(7):3846-58. PubMed ID: 25609801
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle.
    Albecka A; Belouzard S; Op de Beeck A; Descamps V; Goueslain L; Bertrand-Michel J; Tercé F; Duverlie G; Rouillé Y; Dubuisson J
    Hepatology; 2012 Apr; 55(4):998-1007. PubMed ID: 22121002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV.
    Jahan S; Khaliq S; Samreen B; Ijaz B; Khan M; Ahmad W; Ashfaq UA; Hassan S
    Virol J; 2011 Jun; 8():295. PubMed ID: 21663667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents.
    Poumbourios P; Drummer HE
    Antivir Chem Chemother; 2007; 18(4):169-89. PubMed ID: 17907376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections.
    Colpitts CC; Verrier ER; Baumert TF
    ACS Infect Dis; 2015 Sep; 1(9):420-7. PubMed ID: 27617925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies.
    Zona L; Tawar RG; Zeisel MB; Xiao F; Schuster C; Lupberger J; Baumert TF
    Viruses; 2014 Feb; 6(2):875-92. PubMed ID: 24553110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.